Jubilant Pharmaceuticals SA
Jubilant Pharmaceuticals reported revenue of 993,275 € for the 2026 financial year (annual accounts filed with the NBB on 30 Oct 2026).
The score of Jubilant Pharmaceuticals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Revenue +46 % Total assets -26 %
Accounts of the company itself (not consolidated).
The full file covers 12 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Jubilant Pharmaceuticals's annual accounts
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | 993,275 € | ||||
| Net result | 43,337 € | ||||
| Equity | −€1.00m | ||||
| Cash | 11,755 € | ||||
| Total assets | 491,957 € |
Filed annual accounts
- Year ended 31 Mar 2026filed on 30 Oct 2026
- Year ended 31 Mar 2025filed on 06 Oct 2025
- Year ended 31 Mar 2024filed on 02 Oct 2024
- Year ended 31 Mar 2023filed on 31 Oct 2023
- Year ended 31 Mar 2022filed on 28 Oct 2022
Jubilant Pharmaceuticals's financial analysis
- Solvency-203.9%sector median: 57.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Jubilant Pharmaceuticals
Jubilant Pharmaceuticals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0454.891.594
- VAT number
- BE0454891594
- Peppol
- Registered · 0208:0454891594 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 14 Apr 1995
- Registered office
- 9820 Merelbeke-Melle
- Latest accounts
- 2026 · filed on 30 Oct 2026
- Activity
- Other legal activities (NACE 69109)
Jubilant Pharmaceuticals (SA) has been based in Merelbeke-Melle since 1995, active in: other legal activities. For 2026, it reports revenue of 993,275 €, a net profit of 43,337 € and equity of −€1.00m. Its solvency stands at -203.9%, below the median of its sector (57.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Jubilant Pharmaceuticals
Companies in the same business, of comparable size and area, outside its group.
- QualiThink Business and other management consultancy activities Chastre · balance sheet 523,033 €
- Neo Medical Business and other management consultancy activities Bierbeek · balance sheet 412,151 €
- FLGM Consulting Research and experimental development on natural sciences and engineering Burdinne · balance sheet 912,045 €
Frequently asked questions about Jubilant Pharmaceuticals
What is the revenue of Jubilant Pharmaceuticals?
According to the 2026 annual accounts filed with the NBB, the revenue of Jubilant Pharmaceuticals amounts to 993,275 €.
What is the VAT number of Jubilant Pharmaceuticals?
In Belgium, the VAT number is the company number prefixed with BE: BE0454891594 for Jubilant Pharmaceuticals, if the company is VAT-registered. Its company number (CBE) is 0454.891.594.
Where is the registered office of Jubilant Pharmaceuticals?
According to the CBE register, the registered office of Jubilant Pharmaceuticals is in 9820 Merelbeke-Melle.
What is the equity of Jubilant Pharmaceuticals?
At the close of the 2026 financial year, the equity of Jubilant Pharmaceuticals amounts to -1,003,129 €, a solvency of -203.9% of total assets.
Who manages Jubilant Pharmaceuticals?
The register lists 3 active mandates at Jubilant Pharmaceuticals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Jubilant Pharmaceuticals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →